Articles By Janet Pope, MD, MPH, FRCPC
Here’s what will change my practice in Rheumatoid Arthritis
28 November 2023
Here's what I learned at ACR23 that will change the way I practice in rheumatoid arthritis.
Read Article
JAKi and TYK2i: What to use and when?
20 November 2023
You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.
Read Article
Who gives a ‘JAK’ why and how they work, as long as they do!
12 November 2023
Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.
Read Article
Combining a Tyk2 inhibitor with a JAKi in RA?
08 June 2023
At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.
Read Article
New treatment for Takayasu’s arteritis?
07 June 2023
Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.
Read Article
The future of lupus treatment is oral therapies?
01 June 2023
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. But, what about the JAKis and Tyk2 oral drugs in SLE?
Read Article
Why treatment of pre-RA isn't ready for prime time
18 November 2022
The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?
Read Article
Medication adherence is a problem
13 November 2022
Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects). This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
Read Article
Don’t be ‘ticked’: TYK2 is not a JAK!
12 November 2022
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
Read Article
CV risk factors not equal when considering magnitude of risk
10 June 2022
What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists.
Read Article